Orchard Therapeutics Completes ADS Ratio Change
BOSTON and LONDON, March 10, 2023 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq:ORTX), a global gene therapy leader, today announced that the Company’s previously disclosed change to its American Depositary Share (“ADS”) to ordinary share ratio has been made effective. The ratio has changed from one ADS to one ordinary share to the new ratio of one ADS to ten ordinary shares.
Related news for (ORTX)
- Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome
- Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium
- Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy
- Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases
- Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD